ProPhase Labs (NASDAQ:PRPH) Shares Cross Below 200-Day Moving Average – Time to Sell?

Shares of ProPhase Labs, Inc. (NASDAQ:PRPH) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.26 and traded as low as $0.0750. ProPhase Labs shares last traded at $0.0756, with a volume of 4,041 shares trading hands.

ProPhase Labs Stock Performance

The company has a debt-to-equity ratio of 0.14, a current ratio of 0.14 and a quick ratio of 0.14. The stock has a market cap of $575,101.00, a PE ratio of -0.02 and a beta of 0.09. The business has a 50 day moving average price of $0.11 and a two-hundred day moving average price of $0.25.

Institutional Investors Weigh In On ProPhase Labs

A hedge fund recently raised its position in ProPhase Labs stock. Susquehanna International Group LLP grew its position in shares of ProPhase Labs, Inc. (NASDAQ:PRPH) by 290.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 397,914 shares of the company’s stock after acquiring an additional 295,899 shares during the period. Susquehanna International Group LLP owned about 0.96% of ProPhase Labs worth $182,000 as of its most recent SEC filing. 9.45% of the stock is owned by institutional investors and hedge funds.

About ProPhase Labs

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.